Heparin-like heparan sulfate from rabbit cartilage

Glycobiology

Volumn 22, Issue 2, 2012, Pages 248-257

  Parra, Alessandro ^a   Veraldi, Noemi ^c   Locatelli, Manuela ^a   Fini, Milena ^b   Martini, Lucia ^b   Torri, Giangiacomo ^c   Sangiorgi, Luca ^a   Bisio, Antonella ^c  

^a SSD Genetica Medica e Malattie Rare Ortopediche   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

Author keywords

cartilage; heparan sulfate; mass spectrometry; NMR; rabbit

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; CHONDROITIN SULFATE; DISACCHARIDE; GLUCOSAMINE SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HYALURONIC ACID; IDURONIC ACID; PENTASACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CARBOHYDRATE ANALYSIS; CARBOHYDRATE METABOLISM; CARBOHYDRATE SYNTHESIS; CONTROLLED STUDY; FEASIBILITY STUDY; FRACTIONATION; GROWTH PLATE; HETERONUCLEAR NUCLEAR MAGNETIC RESONANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RABBIT; SULFATION;

ANIMALS; BINDING SITES; CARTILAGE, ARTICULAR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISACCHARIDES; GLUCOSAMINE; GROWTH PLATE; HEPARIN; HEPARITIN SULFATE; IDURONIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; OLIGOSACCHARIDES; RABBITS;

ORYCTOLAGUS CUNICULUS;

EID: 84855864366     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwr143     Document Type: Article

References (59)

1. Ahn JI, Erdin RA, Smith R, Canale ST, Hasty KA. 2006. Chondrocyte injection in distraction epiphysiolysis (rabbit model). J Orthop Res. 24(3):355-365. (Pubitemid 43772996)
2. Ahn J, Lüdecke HJ, Lindow S, Horton WA, Lee B, Wagner MJ, Horsthemke B, Wells DE. 1995. Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1). Nat Genet. 11:137-143.
3. Axelsson I, Berman I, Pita JC. 1983. Proteoglycans from rabbit articular and growth plate cartilage. J Biol Chem. 258:8915-8921.
4. Barbucci R, Lamponi S, Borzacchiello A, Ambrosio L, Fini M, Torricelli P, Giardino R. 2002. Hyaluronic acid hydrogel in the treatment of osteoar-thritis. Biomaterials. 23(23):4503-4513. (Pubitemid 36151602)
5. Bishop JR, Schuksz M, Esko JD. 2007. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 446(7139):1030-1037. (Pubitemid 46676065)
6. Bromley M, Fisher WD, Woolley DE. 1984. Mast cells at sites of cartilage erosion in the rheumatoid joint. Ann Rheum Dis. 43:76-79. (Pubitemid 14152982)
7. Carey DJ. 1997. Syndecans: Multifunctional cell-surface co-receptors. Biochem J. 327:1-16. (Pubitemid 27455453)
8. Casu B, Naggi A, Torri G. 2010. Heparin derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol. 29:442-452.
9. Cheung PK, McCormick C, Crawford BE, Esko JD, Tufaro F, Duncan G. 2001. Etiological point mutations in the hereditary multiple exostoses gene EXT1: A functional analysis of heparan sulfate polymerase activity. Am J Hum Genet. 69:55-66. (Pubitemid 32614018)
10. Cockin GH, Huckerby TN, Nieduszynski IA. 1986. High-field n.m.r. studies of keratan sulphates. 1H and 13C assignments of keratan sulphate from shark cartilage. Biochem J. 236:921-924. (Pubitemid 16067138)
11. Cook A, Raskind W, Blanton SH, Pauli RM, Gregg RG, Francomano CA, Puffenberger E, Conrad EU, Schmale G, Schellenberg G, et al. 1993. Genetic heterogeneity in families with hereditary multiple exostoses. Am J Hum Genet. 53(1):71-79. (Pubitemid 23313737)
12. Couchman JR. 2010. Transmembrane signaling proteoglycans. Ann Rev Cell Dev Biol. 26:89-114.
13. DeBaun MR, Ess J, Saunders S. 2001. Simpson Golabi Behmel Syndrome: Progress towards understanding the molecular basis of overgrowth, malformation and cancer predisposition. Mol Genet Metab. 72:279-286. (Pubitemid 34171422)
14. DeCat B, David G. 2001. Developmental roles of the glypicans. Cell Dev Biol. 12:117-125.
15. De Franceschi L, Grigolo B, Roseti L, Facchini A, Fini M, Giavaresi G, Tschon M, Giardino R. 2005. Transplantation of chondrocytes seeded on collagen-based scaffold in cartilage defects in rabbits. J Biomed Mater Res A. 75(3):612-622. (Pubitemid 47233445)
16. Dreyfuss JL, Regatieri CV, Jarrouge TR, Cavalheiro RP, Sampaio LO, Nader HB. 2009. Heparan sulfate proteoglycans: Structure, protein interactions and cell signaling. Ann Braz Acad Sci. 81(3):409-429.
17. Duncan G, McCormick C, Tufaro F. 2001. The link between heparan sulfate and hereditary bone disease: Finding a function for the EXT family of putative tumor suppressor proteins. J Clin Invest. 108:511-516. (Pubitemid 32777728)
18. Esko JD, Kimata K, Lindahl U. 2009. Proteoglycans and sulfated glycosami-noglycans. In: Varki A, Cummings R, Esko J, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors. Essential of Glycobiology. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press.
19. Esko JD, Selleck SB. 2002. Order out of chaos: Assembly of ligand binding sites in heparan sulfate. Ann Rev Biochem. 71:435-471. (Pubitemid 34800227)
20. Filmus J, Selleck SB. 2001. Glypicans proteoglycans with a surprise. J Clin Invest. 108:497-501.
21. Fransson LA, Silverberg I, Carlstedt I. 1985. Structure of the heparan sulfate-protein linkage region. Demonstration of the sequence galactosyl-galactosyl-xylose-2-phosphate. J Biol Chem. 260:14722-14726.
22. Grigolo B, Roseti L, Fiorini M, Fini M, Giavaresi G, Aldini NN, Giardino R, Facchini A. 2001. Transplantation of chondrocytes seeded on a hyaluronan derivative (Hyaff-11) into cartilage defects in rabbits. Biomaterials. 22 (17):2417-2424. (Pubitemid 32666233)
23. Grobe K, Ledin J, Ringvall M, Holmborn K, Forsberg E, Esko JD, Kjellén L. 2002. Heparan sulfate and development: Differential roles of the N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes. Biochim Biophys Acta. 1573(3):209-215. (Pubitemid 35335430)
24. Guerrini M, Bisio A, Torri G. 2001. Combined quantitative 1H and 13C nuclear magnetic resonance spectroscopy for characterization of heparin preparations. Semin Thromb Hemost. 27(5);473-482. (Pubitemid 32989371)
25. Guerrini M, Guglieri S, Naggi A, Sasisekharan R, Torri G. 2007. Low molecular weight heparins: Structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost. 33(5):478-487. (Pubitemid 47105737)
26. Guerrini M, Naggi A, Guglieri S, Santarsiero R, Torri G. 2005. Complex gly-cosaminoglycans: Profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal Biochem. 337:35-47. (Pubitemid 40092776)
27. Ha YW, Jeon BT, Moon SH, Toyoda H, Toida T, Linhardt RJ, Kim YS. 2005. Characterization of heparan sulfate from the unossified antler of Cervus elaphus. Carbohydr Res. 340:411-416. (Pubitemid 40186768)
28. Häcker U, Nybakken K, Perrimon N. 2005. Heparan sulphate proteoglycans: The sweet side of development. Nat Rev Mol Cell Biol. 6:530-541. (Pubitemid 40943044)
29. Heinegård D. 2009. Proteoglycans and more-from molecules to biology. Int J Exp Path. 90:575-586.
30. Hounsell EF, Feeney J, Scudder P, Tang PW, Feizi T. 1986. 1H-NMR studies at 500 MHz of a neutral disaccharide and sulphated di-, tetra-, hexa-and larger oligosaccharides obtained by endo-p-galactosidase treatment of keratan sulphate. Eur J Biochem. 157:375-384. (Pubitemid 16077819)
31. Iacomini M, Casu B, Guerrini M, Naggi A, Pirola A, Torri G. 1999. "Linkage region" sequences of heparins and heparan sulfates: Detection and quantification by nuclear magnetic resonance spectroscopy. Anal Biochem. 274(1):50-58. (Pubitemid 29466354)
32. Iozzo RV 2005. Basement membrane proteoglycans: From cellar to ceiling. Nat Rev Mol Cell Biol. 6:646-656. (Pubitemid 41081268)
33. Kobayashi S, Morimoto K, Shimizu T, Takahashi M, Kurosawa H, Shirasawa T. 2000. Association of EXT1 and EXT2, hereditary multiple exostoses gene products, in Golgi apparatus. Biochem Biophys Res Comm. 268:860-867. (Pubitemid 30150882)
34. Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K. 1998. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem. 273:26265-26268. (Pubitemid 28471622)
35. Lindahl U, Kuschke-Gullberg M, Kjellen L. 1998. Regulated diversity of heparan sulfate. J Biol Chem. 273:24979-24982. (Pubitemid 28443251)
36. Linhardt RJ. 2003. Heparin: Structure and activity. J Med Chem. 46:2551-2564.
37. Liu Z, Lavine KJ, Hung IH, Ornitz DM. 2007. FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. Dev Biol. 302:80-91. (Pubitemid 46096925)
38. McCormick C, Duncan G, Goutsos KT, Tufaro F. 2000. The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulphate. Proc Natl Acad Sci USA. 97:668-673. (Pubitemid 30070367)
39. Mohammadi M, Olsen SK, Goetz R. 2005. A protein canyon in the FGF-FGF receptor dimer selects from an à la carte menu of heparan sulfate motifs. Curr Opin Struct Biol. 15(5):506-516. (Pubitemid 41393481)
40. Ornitz DM. 2005. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev. 16:205-213. (Pubitemid 40616117)
41. Presto J, Thuveson M, Carlsson P, Busse M, Wilén M, Eriksson I, Kusche-Gullberg M, Kjellén L. 2008. Heparan sulfate biosynthesis enzymes EXT1 and EXT2 affect NDST1 expression and heparan sulfate sulfation. Proc Natl Acad Sci USA. 105:4751-4756. (Pubitemid 351753818)
42. Princivalle M, Agostini A. 2002. Developmental roles of heparan sulfate pro-teoglycans: A comparative review in Drosophila, mouse and human. Int J Dev Biol. 46:267-278. (Pubitemid 34619712)
43. Smith RL, Nagel DA. 1983. Effects of pulsing electromagnetic fields on bone growth and articular cartilage. Clin Orthop Relat Res. 181:27782.
44. Smith SML, West LA, Govindraj P, Zhang X, Ornitz DM, Hassell JR. 2007. Heparan and chondroitin sulfate on growth plate perlecan mediate binding and delivery of FGF-2 to FGF receptors. Matrix Biol. 26:175-184. (Pubitemid 46401230)
45. Stickens D, Clines G, Burbee D, Ramos P, Thomas S, Hogue D, Hecht JT, Lovett M, Evans GA. 1996. The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes. Nat Genet. 14:25-32. (Pubitemid 26301543)
46. Sugahara K, Ohi Y, Harada T. 1992. Structural studies on sulfated oligosac-charides derived from the carbohydrate-protein linkage region of chondroi-tin 6-sulfate proteoglycans of shark cartilage. Six compounds containing 0 or 1 sulfate and/or phosphate residue. J Biol Chem. 267:6027-6035.
47. Sundaram M, Qi Y, Shriver Z, Liu D, Zhao G, Venkataraman G, Langer R, Sasisekharan R. 2003. Rational design of low-molecular weight heparins with improved in vivo activity. Proc Natl Acad Sci USA. 100:651-656. (Pubitemid 36126107)
48. Toma L, Berninsone P, Hirschberg CB. 1998. The putative heparin-specific N-acetylglucosaminyl N-deacetylase/N-sulfotransferase also occurs in non-heparin-producing cells. J Biol Chem. 273:22458-22465. (Pubitemid 28399811)
49. Torri G, Bisio A, Casu B, Guerrini M, Naggi A, Nogueira Barbosa MC, Sciorati C, Silvestro L. 1994. Nuclear magnetic resonance analysis of human urines. Influence of intravenous and oral administration of glycosa-minoglycans. Semin Thromb Hemost. 20:144-151. (Pubitemid 24263663)
50. Tumova S, Woods A, Couchman JR. 2000. Heparan sulfate proteoglycans on the cell surface: Versatile coordinators of cellular functions. Int J Biochem Cell Biol. 32:269-288. (Pubitemid 30069970)
51. Valstar MJ, Ruijiter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA. 2008. Sanfilippo syndrome: A mini-review. J Inherit Metab Dis. 31:240-252.
52. Vincent JP. 2003. Membranes, trafficking, and signaling during animal development. Cell. 112:745-749.
53. Vincent JP, Dubois L. 2002. Morphogen transport along epithelia, an integrated trafficking problem. Dev Cell. 3:615-623. (Pubitemid 35339480)
54. Warda M, Toida T, Zhang F, Sun P, Munoz E, Xie J, Linhardt RJ. 2006. Isolation and characterization of heparan sulfate from various murine tissues. Glycoconj J. 23:555-563. (Pubitemid 44477397)
55. Whitelock JM, Iozzo RV. 2005. Heparan sulfate: A complex polymer charged with biological activity. Chem Rev. 105:2745-2764. (Pubitemid 41055329)
56. Wuyts W, Van Hul W. 2000. Molecular basis of multiple exostoses: Mutations in the EXT1 and EXT2 genes. Hum Mutat. 15(3):220-227. (Pubitemid 30132156)
57. Wuyts W, Van Hul W, De Boulle K, Hendrickx J, Bakker E, Vanhoenacker F, Mollica F, Lüdecke HJ, Sayli BS, Pazzaglia UE, et al. 1998. Mutations in the EXT1 and EXT2 genes in hereditary multiple exostoses. Am J Hum Genet. 62(2):346-354. (Pubitemid 28110777)
58. Wuyts W, Van Hul W, Wauters J, Nemtsova M, Reyniers E, Van Hul EV, De Boulle K, de Vries BB, Hendrickx J, Herrygers I, et al. 1996. Positional cloning of a gene involved in hereditary multiple exostoses. Hum Mol Genet. 5:1547-1557. (Pubitemid 26328870)
59. Xiao Z, Tappen BR, Ly M, Zhao W, Canova LP, Guan H, Linhardt RJ. 2011. Heparin mapping using heparin lyases and generation of a novel low molecular weight heparin. Med Chem. 54:603-610.